On the Effects of Misclassification in Estimating Efficacy With Application to Recent COVID-19 Vaccine Trials
John P. Buonaccorsi
doi: https://doi.org/10.1101/2020.12.04.20244244
John P. Buonaccorsi
Dept. of Mathematics and Statistics, University of Massachusetts-Amherst

Data Availability
Data taken off web and public press reporting COVID-19 vaccine trials by Moderna and Pfizer
Posted April 03, 2021.
On the Effects of Misclassification in Estimating Efficacy With Application to Recent COVID-19 Vaccine Trials
John P. Buonaccorsi
medRxiv 2020.12.04.20244244; doi: https://doi.org/10.1101/2020.12.04.20244244
Subject Area
Subject Areas
- Addiction Medicine (423)
- Allergy and Immunology (746)
- Anesthesia (217)
- Cardiovascular Medicine (3216)
- Dermatology (270)
- Emergency Medicine (476)
- Epidemiology (13229)
- Forensic Medicine (19)
- Gastroenterology (887)
- Genetic and Genomic Medicine (5054)
- Geriatric Medicine (469)
- Health Economics (772)
- Health Informatics (3174)
- Health Policy (1126)
- Hematology (421)
- HIV/AIDS (998)
- Medical Education (467)
- Medical Ethics (125)
- Nephrology (513)
- Neurology (4795)
- Nursing (253)
- Nutrition (712)
- Oncology (2470)
- Ophthalmology (700)
- Orthopedics (278)
- Otolaryngology (337)
- Pain Medicine (319)
- Palliative Medicine (89)
- Pathology (528)
- Pediatrics (1274)
- Primary Care Research (548)
- Public and Global Health (7357)
- Radiology and Imaging (1666)
- Respiratory Medicine (965)
- Rheumatology (472)
- Sports Medicine (413)
- Surgery (532)
- Toxicology (69)
- Transplantation (229)
- Urology (199)